Evaluation of 7 serum biomarkers and uterine artery doppler ultrasound for first-trimester prediction of preeclampsia: A systematic review

Obstetrical and Gynecological Survey

Volumn 66, Issue 4, 2011, Pages 225-239

  Kuc, Sylwia ^a   Wortelboer, Esther J ^a   Van Rijn, Bas B ^a,b   Franx, Arie ^b   Visser, Gerard H A ^b   Schielen, Peter C J I ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ADAM PROTEIN; ANGIOGENIC FACTOR; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; INHIBIN A; PLACENTAL PROTEIN 13; PROTEIN ADAM 12; PROTEIN P1GF; PROTEIN PAPP A; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG;

DIAGNOSTIC ACCURACY; DOPPLER ECHOGRAPHY; FALSE POSITIVE RESULT; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY OUTCOME; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; UTERINE ARTERY;

BIOLOGICAL MARKERS; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; ULTRASONOGRAPHY, DOPPLER; UTERINE ARTERY;

EID: 79961078416     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3182227027     Document Type: Review

References (103)

1. Saftlas AF, Olson DR, Franks AL, et al. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol. 1990;163:460-465. (Pubitemid 20287609)
2. Geographic variation in the incidence of hypertension in pregnancy. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol. 1988;158:80-83.
3. Roberts JM, Pearson GD, Cutler JA, et al. Summary of the NHLBI Working Group on research on hypertension during pregnancy. Hypertens Pregnancy. 2003;22:109-127. (Pubitemid 37521363)
4. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-799. (Pubitemid 40311367)
5. Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006;11: 309-316. (Pubitemid 44038703)
6. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592-1594. (Pubitemid 40807500)
7. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol. 1998;16:5-15. (Pubitemid 28285299)
8. Visser N, van Rijn BB, Rijkers GT, et al. Inflammatory changes in preeclampsia: current understanding of the maternal innate and adaptive immune response. Obstet Gynecol Surv. 2007;62:191-201. (Pubitemid 46294788)
9. Roberts JM, Lain KY. Recent insights into the pathogenesis of pre-eclampsia. Placenta. 2002;23:359-372. (Pubitemid 41110499)
10. Steegers EA, von DP, Duvekot JJ, et al. Pre-eclampsia. Lancet. 2010;376:631-644.
11. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008;51:970-975. (Pubitemid 351398986)
12. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol. 2004;104:1367-1391. (Pubitemid 40458737)
13. Cnossen JS, Vollebregt KC, de VN, et al. Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis. BMJ. 2008;336:1117-1120. (Pubitemid 351731742)
14. Akolekar R, Zaragoza E, Poon LC, et al. Maternal serum placental growth factor at 110 to 136 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2008;32:732-739.
15. Wortelboer EJ, Koster MP, Cuckle HS, et al. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset preeclampsia. BJOG. 2010;117:1384-1389.
16. Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004;191:1446-1451. (Pubitemid 39421612)
17. Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn. 2008;28:212-216. (Pubitemid 351427940)
18. Spencer K, Cowans NJ, Nicolaides KH. Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet Gynecol. 2008;32:622-626.
19. Franx A. Predictiemodellen voor pre-eclampsie. Slager E, eds. Conference Proceeding: Reproductieve geneeskunde, gynaecologie en obstetrie anno 2009. The Netherlands: Haarlem, DCHG, 2009;1:243-250.
20. Brown MA, Lindheimer MD, de SM, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20:IX-XIV. (Pubitemid 32672922)
21. von DP, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22:143-148. (Pubitemid 37521365)
22. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
23. Akolekar R, Syngelaki A, Beta J, et al. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diagn. 2009;29:1103-1108.
24. Chafetz I, Kuhnreich I, Sammar M, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007;197:35-37.
25. Gonen R, Shahar R, Grimpel YI, et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG. 2008;115:1465-1472.
26. Khalil A, Cowans NJ, Spencer K, et al. First trimester maternal serum placental protein 13 for the prediction of preeclampsia in women with a priori high risk. Prenat Diagn. 2009;29:781-789.
27. Nicolaides KH, Bindra R, Turan OM, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol. 2006;27:13-17. (Pubitemid 43129084)
28. Romero R, Kusanovic JP, Than NG, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol. 2008;199:122.
29. Spencer K, Cowans NJ, Chefetz I, et al. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;29:128-134. (Pubitemid 46326583)
30. Foidart JM, Munaut C, Chantraine F, et al. Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. Ultrasound Obstet Gynecol. 2010;35:680-687.
31. Audibert F, Boucoiran I, An N, et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol. 2010;203:383-388.
32. Hedley PL, Placing S, Wojdemann K, et al. Free leptin index and PAPP-A: a first trimester maternal serum screening test for pre-eclampsia. Prenat Diagn. 2010;30:103-109.
33. Goetzinger KR, Singla A, Gerkowicz S, et al. Predicting the risk of pre-eclampsia between 11 and 13 weeks' gestation by combining maternal characteristics and serum analytes, PAPP-A and free beta-hCG. Prenat Diagn. 2010;30:1138-1142.
34. Brameld KJ, Dickinson JE, O'Leary P, et al. First trimester predictors of adverse pregnancy outcomes. Aust N Z J Obstet Gynaecol. 2008;48:529-535.
35. Ong CY, Liao AW, Spencer K, et al. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG. 2000;107:1265-1270.
36. Pilalis A, Souka AP, Antsaklis P, et al. Screening for preeclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation. Ultrasound Obstet Gynecol. 2007;29:135-140. (Pubitemid 46326584)
37. Poon LC, Maiz N, Valencia C, et al. First-trimester maternal serum pregnancy-associated plasma protein-A and preeclampsia. Ultrasound Obstet Gynecol. 2009;33:23-33.
38. Smith GC, Stenhouse EJ, Crossley JA, et al. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87: 1762-1767. (Pubitemid 34615266)
39. Spencer K, Yu CK, Cowans NJ, et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn. 2005;25:949-953. (Pubitemid 41494994)
40. Herraiz I, Lopez-Jimenez EA, Garcia-Burguillo A, et al. Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation. Ultrasound Obstet Gynecol. 2009;33:518-523.
41. Napolitano R, Rajakulasingam R, Memmo A, et al. Uterine artery Doppler screening for preeclampsia: comparison of the lower, mean and higher first trimester pulsatility indeces. Ultrasound Obstet Gynecol. 2011;37:534-537.
42. Hafner E, Metzenbauer M, Stumpflen I, et al. First trimester placental and myometrial blood perfusion measured by 3D power Doppler in normal and unfavourable outcome pregnancies. Placenta. 2010;31:756-763.
43. Fratelli N, Rampello S, Guala M, et al. Transabdominal uterine artery Doppler between 11 and 14 weeks of gestation for the prediction of outcome in high-risk pregnancies. J Matern Fetal Neonatal Med. 2008;21:403-406. (Pubitemid 351999176)
44. Gomez O, Martinez JM, Figueras F, et al. Uterine artery Doppler at 11-14 weeks of gestation to screen for hypertensive disorders and associated complications in an unselected population. Ultrasound Obstet Gynecol. 2005;26: 490-494. (Pubitemid 41634533)
45. Melchiorre K, Wormald B, Leslie K, et al. First-trimester uterine artery Doppler indices in term and preterm preeclampsia. Ultrasound Obstet Gynecol. 2008;32:133-137.
46. Pilalis A, Souka AP, Antsaklis P, et al. Screening for preeclampsia and small for gestational age fetuses at the 11-14 weeks scan by uterine artery Dopplers. Acta Obstet Gynecol Scand. 2007;86:530-534. (Pubitemid 46676307)
47. Plasencia W, Maiz N, Bonino S, et al. Uterine artery Doppler at 11+0 to 13+6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;30:742-749. (Pubitemid 47612696)
48. Plasencia W, Maiz N, Poon L, et al. Uterine artery Doppler at 11+0 to 13+6 weeks and 21+0 to 24+6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2008;32:138-146.
49. Melchiorre K, Leslie K, Prefumo F, et al. First-trimester uterine artery Doppler indices in the prediction of smallfor-gestational age pregnancy and intrauterine growth restriction. Ultrasound Obstet Gynecol. 2009;33:524-529.
50. Poon LC, Staboulidou I, Maiz N, et al. Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11-13 weeks. Ultrasound Obstet Gynecol. 2009;34:142-148.
51. Poon LC, Karagiannis G, Leal A, et al. Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks. Ultrasound Obstet Gynecol. 2009;34:497-502.
52. Rizzo G, Capponi A, Cavicchioni O, et al. First trimester uterine Doppler and three-dimensional ultrasound placental volume calculation in predicting pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2008;138:147-151. (Pubitemid 351726049)
53. Smith GC, Crossley JA, Aitken DA, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007;109:1316-1324. (Pubitemid 46869870)
54. Gilpin BJ, Loechel F, Mattei MG, et al. A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem. 1998;273:157-166. (Pubitemid 28042189)
55. Gack S, Marme A, Marme F, et al. Preeclampsia: increased expression of soluble ADAM 12. J Mol Med. 2005;83:887-896. (Pubitemid 41598689)
56. Laigaard J, Sorensen T, Placing S, et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol. 2005;106:144-149. (Pubitemid 40898447)
57. Poon LC, Chelemen T, Granvillano O, et al. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol. 2008;112:1082-1090.
58. Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. 2010;8:102.
59. Said ME, Campbell DM, Azzam ME, et al. Beta-human chorionic gonadotrophin levels before and after the development of pre-eclampsia. Br J Obstet Gynaecol. 1984;91:772-775. (Pubitemid 14057173)
60. Sorensen TK, Williams MA, Zingheim RW, et al. Elevated second-trimester human chorionic gonadotropin and subsequent pregnancy-induced hypertension. Am J Obstet Gynecol. 1993;169:834-838. (Pubitemid 23317514)
61. Lee LC, Sheu BC, Shau WY, et al. Mid-trimester beta-hCG levels incorporated in a multifactorial model for the prediction of severe pre-eclampsia. Prenat Diagn. 2000;20:738-743.
62. Canini S, Prefumo F, Pastorino D, et al. Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Fertil Steril. 2008;89:174-178.
63. Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of preeclampsia. Prenat Diagn. 2008;28:7-10. (Pubitemid 351251982)
64. Yaron Y, Ochshorn Y, Heifetz S, et al. First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome. Fetal Diagn Ther. 2002;17: 352-356. (Pubitemid 36160157)
65. Zwahlen M, Gerber S, Bersinger NA. First trimester markers for pre-eclampsia: placental vs. non-placental protein serum levels. Gynecol Obstet Invest. 2007;63:15-21. (Pubitemid 46034198)
66. Petraglia F, Vaughan J, Vale W. Inhibin and activin modulate the release of gonadotropin-releasing hormone, human chorionic gonadotropin, and progesterone from cultured human placental cells. Proc Natl Acad Sci USA. 1989;86:5114-5117. (Pubitemid 19182243)
67. Birdsall M, Ledger W, Groome N, et al. Inhibin A and activin A in the first trimester of human pregnancy. J Clin Endocrinol Metab. 1997;82:1557-1560. (Pubitemid 27200434)
68. Muttukrishna S, Knight PG, Groome NP, et al. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet. 1997;349:1285-1288. (Pubitemid 27192471)
69. Salomon LJ, Benattar C, Audibert F, et al. Severe preeclampsia is associated with high inhibin A levels and normal leptin levels at 7 to 13 weeks into pregnancy. Am J Obstet Gynecol. 2003;189:1517-1522. (Pubitemid 38056417)
70. Sebire NJ, Roberts L, Noble P, et al. Raised maternal serum inhibin A concentration at 10 to 14 weeks of gestation is associated with pre-eclampsia. BJOG. 2000;107:795-797. (Pubitemid 30311918)
71. Sekizawa A, Purwosunu Y, Yoshimura S, et al. PP13 mRNA expression in trophoblasts from preeclamptic placentas. Reprod Sci. 2009;16:408-413.
72. Burger O, Pick E, Zwickel J, et al. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta. 2004;25:608-622. (Pubitemid 38950314)
73. Than NG, Pick E, Bellyei S, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem. 2004;271: 1065-1078. (Pubitemid 38373040)
74. Visegrady B, Than NG, Kilar F, et al. Homology modelling and molecular dynamics studies of human placental tissue protein 13 (galectin-13). Protein Eng. 2001;14:875-880. (Pubitemid 34024179)
75. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008; 21:9-23.
76. Lockwood CJ, Krikun G, Caze R, et al. Decidual cellexpressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis. Ann N Y Acad Sci. 2008;1127:67-72. (Pubitemid 351563106)
77. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004; 190:1541-1547.
78. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350:672-683. (Pubitemid 38364626)
79. Clark DE, Smith SK, Licence D, et al. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol. 1998;159:459-467. (Pubitemid 29003021)
80. Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002;160:1405-1423. (Pubitemid 34411644)
81. Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008;21:279-287. (Pubitemid 351652513)
82. Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89:770-775. (Pubitemid 38269892)
83. Vatten LJ, Eskild A, Nilsen TI, et al. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol. 2007; 196:239-236.
84. Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50:137-142. (Pubitemid 46986022)
85. Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003;188:177-182. (Pubitemid 36135616)
86. Thadhani R, Ecker JL, Mutter WP, et al. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension. 2004;43:988-992. (Pubitemid 38579903)
87. Bersinger NA, Smarason AK, Muttukrishna S, et al. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens Pregnancy. 2003;22:45-55. (Pubitemid 36205807)
88. Guibourdenche J, Frendo JL, Pidoux G, et al. Expression of pregnancy-associated plasma protein-A (PAPP-A) during human villous trophoblast differentiation in vitro. Placenta. 2003;24:532-539. (Pubitemid 37184775)
89. Lawrence JB, Oxvig C, Overgaard MT, et al. The insulinlike growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancyassociated plasma protein-A. Proc Natl Acad Sci USA. 1999;96:3149-3153. (Pubitemid 29148859)
90. Giudice LC, Conover CA, Bale L, et al. Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. J Clin Endocrinol Metab. 2002;87:2359-2366. (Pubitemid 34521531)
91. Irwin JC, Suen LF, Martina NA, et al. Role of the IGF system in trophoblast invasion and pre-eclampsia. Hum Reprod. 1999;14(suppl 2):90-96. (Pubitemid 30040667)
92. Campbell S, az-Recasens J, Griffin DR, et al. New doppler technique for assessing uteroplacental blood flow. Lancet. 1983;1:675-677. (Pubitemid 13158427)
93. Jurkovic D, Jauniaux E, Kurjak A, et al. Transvaginal color Doppler assessment of the uteroplacental circulation in early pregnancy. Obstet Gynecol. 1991;77:365-369.
94. Kaminopetros P, Higueras MT, Nicolaides KH. Doppler study of uterine artery blood flow: comparison of findings in the first and second trimesters of pregnancy. Fetal Diagn Ther. 1991;6:58-64.
95. Ducey J, Schulman H, Farmakides G, et al. A classification of hypertension in pregnancy based on Doppler velocimetry. Am J Obstet Gynecol. 1987;157:680-685. (Pubitemid 17138910)
96. Trudinger BJ, Giles WB, Cook CM. Uteroplacental blood flow velocity-time waveforms in normal and complicated pregnancy. Br J Obstet Gynaecol. 1985;92:39-45. (Pubitemid 15195845)
97. Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. 2008;112:359-372.
98. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330:565.
99. King JC. Maternal obesity, metabolism, and pregnancy outcomes. Annu Rev Nutr. 2006;26:271-291.
100. Kenny LC, Broadhurst DI, Dunn W, et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension. 2010;56:741-749.
101. Rasanen J, Girsen A, Lu X, et al. Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J Proteome Res. 2010;9:4274-4281.
102. Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791-1798. (Pubitemid 46782996)
103. Bujold E, Morency AM, Roberge S, et al. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2009;31:818-826.